Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care.
Rabanal Basalo A, Navarro Pablos M, Viejo Pinero N, Vila Méndez ML, Molina Barcena V, Montilla Bernabé A, Villanueva Morán MDP, Blanco Gallego AM, Guirao Sánchez C, Juárez Antón S, Fernández Rodríguez Á, Revuelta Puigdollers ML, Sarriá Sánchez MT, Martín Alegre C, Martínez Álvarez MÁ, Mestre de Juan M, Mielgo Salvador R, Gijón Seco MT, Saníger Herrera JM, Rodríguez Jiménez ME, Navas de la Peña B, Santa Cruz Hernández J, Abad Esteban AM, Díaz Martín R, García Pérez L, Herrero Vanrell P, Arias de Saavedra Criado MI, Vaquero Vinent A, López Gómez V, Montegrifo Rentero VM, Simón Miguel L, Campo Martos I, Ortiz Zamorano S, Izquierdo Zamarriego MJ, Vázquez Carrión I, López Valero RM, Gil C, Martínez A, Soler López B. Rabanal Basalo A, et al. Among authors: viejo pinero n. Ann Med. 2023;55(2):2268535. doi: 10.1080/07853890.2023.2268535. Epub 2023 Oct 17. Ann Med. 2023. PMID: 37847999 Free PMC article. Clinical Trial.
Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial.
Vila Méndez ML, Antón Sanz C, Cárdenas García ADR, Bravo Malo A, Torres Martínez FJ, Martín Moros JM, Real Torrijos M, Vendrell Covisa JFJ, Guzmán Sierra O, Molina Barcena V, Viejo Pinero N, Fernández Díaz C, Arroyo Burguillo P, Blanco Gallego AM, Guirao Sánchez C, Montilla Bernabé A, Villanueva Morán MDP, Juárez Antón S, Fernández Rodríguez Á, Somoza Calvo MÁ, Cerrada EC, Pérez Mañas G, Sánchez Calso A, Vallejo Somohano F, Cauqui Díaz C, Viñas Fernández G, Molina París J, González Godoy M, Lumbreras García G, Rosado Martín J, Rodríguez Hernández A, López Antúñez S, Vázquez Perfecto G, Marcello Andrés MC, Puente García NM, Gil C, Martínez A, Soler López B. Vila Méndez ML, et al. Among authors: viejo pinero n. J Clin Med. 2022 Dec 24;12(1):142. doi: 10.3390/jcm12010142. J Clin Med. 2022. PMID: 36614943 Free PMC article.